Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2568072 | 0.96 | CYP1A2 (0.38) | CYP1A2CYP2D6 | |
| SCHEMBL34280 | 0.96 | CYP1A2 (0.38) | CYP1A2CYP2D6 | |
| Hydrochloric Acid SCHEMBL153625 | 0.94 | CYP1A2 (0.36) | CYP1A2CYP2D6 | |
| SCHEMBL21808585 | 0.94 | CYP1A2 (0.36) | CYP1A2CYP2D6 | |
| Hydrochloric Acid SCHEMBL5078995 | 0.94 | CYP1A2 (0.36) | CYP1A2CYP2D6 | |
| Hydrochloric Acid SCHEMBL1071947 | 0.94 | CYP1A2 (0.36) | CYP1A2CYP2D6 | |
| Carbimide SCHEMBL7946961 | 0.90 | CYP1A2 (0.34) | CYP1A2CYP2D6 | |
| Carbimide SCHEMBL7717116 | 0.88 | CYP1A2 (0.33) | CYP1A2CYP2D6 | |
| Hydrochloric Acid SCHEMBL29048145 | 0.85 | CYP1A2 (0.32) | CYP1A2CYP2D6 | |
| SCHEMBL16058728 | 0.83 | CYP1A2 (0.31) | CYP1A2CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3927685-A1 | A PROCESS FOR THE SYNTHESIS ANTHRANILIC DIAMIDE COMPOUNDS AND INTERMEDIATES THEREOF | PI Industries Ltd. (IN) | 2021-12-29 | — | — | EP | claimed |
| CN-113614063-A | Method for synthesizing anthranilamide compound and intermediate thereof | PI工业有限公司 | 2021-11-05 | — | — | CN | claimed |
| US-20040048021-A1 | Surface modification of substrates | WAN BARBARA Y F (US) | 2004-03-11 | — | — | US | claimed |
| JP-2002539855-A | — | — | 2002-11-26 | — | — | JP | claimed |
| EP-1178851-A1 | SURFACE MODIFICATION OF SUBSTRATES | GENZYME CORPORATION (US) | 2002-02-13 | — | — | EP | claimed |
| WO-2000056377-A1 | SURFACE MODIFICATION OF SUBSTRATES | GENZYME CORPORATION (US) | 2000-09-28 | — | — | WO | claimed |
| US-5527893-A | Water insoluble derivatives of polyanionic polysaccharides | GENZYME CORPORATION (US) | 1996-06-18 | — | — | US | claimed |
| CN-116547266-A | Synthesis method of anthranilic acid/amide compound and intermediate thereof | 皮埃企业有限公司 | 2023-08-04 | — | — | CN | disclosed |
| EP-3927685-A1 | A PROCESS FOR THE SYNTHESIS ANTHRANILIC DIAMIDE COMPOUNDS AND INTERMEDIATES THEREOF | PI Industries Ltd. (IN) | 2021-12-29 | — | — | EP | disclosed |
| CN-113614063-A | Method for synthesizing anthranilamide compound and intermediate thereof | PI工业有限公司 | 2021-11-05 | — | — | CN | disclosed |
| EP-3766516-A1 | NANOPARTICLE-BASED COMPOSITIONS | President and Fellows of Harvard College (US) | 2021-01-20 | — | — | EP | disclosed |
| US-20200215179-A1 | NANOPARTICLE-BASED COMPOSITIONS | MASSACHUSETTS INSTITUTE OF TECHNOLOGY | 2020-07-09 | — | — | US | disclosed |
| EP-2968510-B1 | NANOPARTICLE-BASED COMPOSITIONS | HARVARD COLLEGE (US) | 2019-10-09 | — | — | EP | disclosed |
| EP-2640426-B1 | IMMUNOSTIMULATORY OLIGONUCLEOTIDES | SELECTA BIOSCIENCES INC (US) | 2016-02-03 | — | — | EP | disclosed |
| US-20160008451-A1 | NANOPARTICLE-BASED COMPOSITIONS | THE BRIGHAM & WOMEN'S HOSPITAL, INC. | 2016-01-14 | — | — | US | disclosed |
| US-8546550-B2 | Immunostimulatory oligonucleotides | SELECTA BIOSCIENCES, INC. (US) | 2013-10-01 | — | — | US | disclosed |
| US-20120213812-A1 | Immunostimulatory Oligonucleotides | SELECTA BIOSCIENCES, INC. | 2012-08-23 | — | — | US | disclosed |
| US-20120177701-A1 | COMPOSITIONS COMPRISING IMMUNOSTIMULATORY NUCLEIC ACIDS AND RELATED METHODS | SELECTA BIOSCIENCES, INC. (US) | 2012-07-12 | — | — | US | disclosed |
| WO-2012042534-A2 | PROCESSES FOR THE PREPARATION OF R-SITAGLIPTIN AND INTERMEDIATES THEREOF | GLENMARK GENERICS LIMITED (IN) | 2012-04-05 | — | — | WO | disclosed |
| WO-2004087650-A2 | PROCESS AND INTERMEDIATES FOR THE PREPARATION OF BETA-AMINO ACID AMIDE DIPEPTIDYL PEPTIDASE-IV INHIBITORS | MERCK & CO. INC. (US) | 2004-10-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160008451-A1 | NANOPARTICLE-BASED COMPOSITIONS | MUC1, TSG101, TLR9 | CYP1A2 4592/4885CYP2D6 4562/4885 |
| US-20120213812-A1 | Immunostimulatory Oligonucleotides | STING1, CD74, DCLRE1B | CYP1A2 4867/4885CYP2D6 4729/4885 |
| US-20200215179-A1 | NANOPARTICLE-BASED COMPOSITIONS | MUC1, TSG101, TLR9 | CYP1A2 4592/4885CYP2D6 4562/4885 |
| US-20120177701-A1 | COMPOSITIONS COMPRISING IMMUNOSTIMULATORY NUCLEIC ACIDS AND RELATED METHODS | STING1, IRF3, IFNG | CYP1A2 4885/4885CYP2D6 4875/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.